Who has been buying Genewon Life Science stock?

2 distinct insiders have filed 0 disclosed insider purchases in Genewon Life Science (011000), most recently on 2026-06-29. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.

How many insider filings does Genewon Life Science have?

Genewon Life Science has 0 buy-side and 4 sell-side disclosures on record, covering ₩257M ($178K) in total reported value, spanning 2024-03-29 to 2026-06-29.

Do insider buys in Korean stocks predict returns?

Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean regulatory filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

Genewon Life Science 011000

Company

진원생명과학Genewon Life Science

Insiders

Buys

Total Value

₩257M ($178K)

Avg Return

+22.84%

Last Filing

2026-06-29

Genewon Life Science (011000) has 0 disclosed insider purchases and 4 disclosed disposals on record, filed by 2 distinct insiders. Together those filings cover ₩257M ($178K) in reported transaction value. The earliest filing StockDrifts holds for Genewon Life Science is dated 2024-03-29; the most recent is 2026-06-29. Across these filings the average return since disclosure is +22.84%, measured from each filing date to the latest available close.

Price & insider activity (12 months)

Recent insider trades

Date	Type	Source	Insider	Position	Shares	Price at filing	Return	Value
2026-06-29	SELL	자본감소	정봉기 Bonggi Jeong	Outside Director	-4.1K	-	-	-
2026-03-27	SELL	Market Sell	박희곤 Park Hee-gon	Managing Director	-33.8K	₩971	+0.0%	₩33M ($23K)
2026-03-25	SELL	Market Sell	박희곤 Park Hee-gon	Managing Director	-30.8K	₩1,004	+3.3%	₩31M ($21K)
2025-08-12	BUY	신규선임	정봉기 Bonggi Jeong	Outside Director	5.1K	₩2,285	-44.5%	₩12M ($8K)
2025-05-15	SELL	Market Sell	최성호 Seongho Choi	thanks	-21.7K	₩2,325	+45.5%	₩51M ($35K)
2025-04-28	SELL	Market Sell	최성호 Seongho Choi	thanks	-64.7K	₩2,205	+42.5%	₩143M ($99K)
2025-03-26	BUY	신규선임	JOELNEAL MASLOW	group leader	20.8K	₩2,070	-38.8%	₩43M ($30K)
2025-01-14	SELL	시간외매매	박영근 Younggeun Park	CEO	-700.0K	₩2,450	+48.3%	₩1.7B ($1.2M)
2024-03-29	BUY	제3자배정유상증자	채재경 Chae Jae-kyung	moving	60.0K	₩2,535	-50.0%	₩152M ($106K)
2024-03-29	BUY	제3자배정유상증자	박영근 Younggeun Park	CEO	1.3M	₩2,535	-50.0%	₩3.3B ($2.3M)
2024-03-29	BUY	제3자배정유상증자	최성호 Seongho Choi	thanks	21.7K	₩2,535	-50.0%	₩55M ($38K)
2024-03-29	BUY	제3자배정유상증자	조병문 Jo Byeong-moon	Managing Director	130.4K	₩2,535	-50.0%	₩331M ($230K)

Frequently asked questions

Who has been buying Genewon Life Science stock?: 2 distinct insiders have filed 0 disclosed insider purchases in Genewon Life Science (011000), most recently on 2026-06-29. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does Genewon Life Science have?: Genewon Life Science has 0 buy-side and 4 sell-side disclosures on record, covering ₩257M ($178K) in total reported value, spanning 2024-03-29 to 2026-06-29.
Do insider buys in Korean stocks predict returns?: Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean regulatory filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

More on this data

Every trade listed above comes from an official regulatory disclosure. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.